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Dialysis rationing in South Africa: 
A global message
JH Dirks1 and NW Levin2,3
Dialysis rationing resulting from limited facilities and health-care 
personnel in low- and middle-income countries such as South Africa 
must be addressed on several fronts. Prevention of kidney disease is 
an essential long-term approach, but in the short term, it is necessary 
to increase access to dialysis and transplantation, and to seek ways to 
limit the ‘brain drain’ to the developed world.
Kidney International (2006) 70, 982–984. doi:10.1038/sj.ki.5001798
Moosa and Kidd1 (this issue) have done 
the nephrology community a service in 
their article on the dangers of rationing 
dialysis treatment in a developing coun-
try. Th is well-documented paper puts on 
the table an array of issues for physicians 
who engage in renal replacement therapy 
(RRT) in low- and middle-income coun-
tries. It is also a challenge to those in the 
developed world, where over 80% of 
dialysis takes place, to heed the call. Th e 
paper describes the 25-year experience 
of the government-requested Western 
Cape Committee in South Africa, com-
posed of a renal-care team that decided 
whether patients presenting with end-
stage renal disease would be accepted 
or rejected for dialysis treatment. Some 
2500 patients were assessed. Those 
accepted were relatively more often 
white, under 40 years old, and likely 
transplantation candidates, had fewer 
complications, and were more often 
employed and married with dependents. 
Th ose rejected, and basically left  to die, 
had more complicated diseases, were 
relatively more oft en non-white, over 
40, and unemployed, lived further from 
the dialysis center, and were generally 
socially disadvantaged. Th e goal of the 
Western Cape Committee of 80 patients 
on dialysis was met, but the percentage 
accepted steadily decreased over time. 
In recent years there was also a signifi -
cant decrease in the number of patients 
receiving transplants.
Th e lack of health-care resources in 
low- and middle-income countries 
either makes RRT unavailable or forces 
life-and-death decisions by individual 
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committees formed for that purpose. 
It is true that the accepted patients, 
at least, are given an opportunity to 
receive quality RRT within a capped 
system, as exists in South Africa and 
indeed elsewhere. Decision making 
was compounded by systemic con-
straints, which included lack of fi nancial 
and human resources, late diagnosis of 
chronic kidney disease, other priorities 
(particularly HIV/AIDS), lack of basic 
amenities, the inaccessibility of rural 
populations, and a lack of government 
will to provide RRT. Interestingly, such 
decision-making committees seem to be 
less common at the present time.
Does rationing of health resources 
have a place in global society? In a 
national health-care system? Certainly 
in most countries, including South 
Africa, the fortunate few can turn to pri-
vate care if it is available. In a public sys-
tem one can understand the economic 
rationale for rationing, but as Moosa 
and Kidd1 point out, it is not likely to 
be a fair process.
Resources are a major issue world-
wide, and we must concede that hemo-
dialysis and peritoneal dialysis are 
expensive treatments, ranging from 
US$30 000 to $60 000 annually in 
developed countries2 and from $6000 
to $40 000 in developing countries.3 
In Ghana, for example, each session 
costs more than $100, which is far out 
of reach for most people. Can dialy-
sis be made more aff ordable? Has this 
question been adequately studied by 
the nephrology community? A group 
of International Society of Nephrology 
(ISN) dialysis physicians has met sev-
eral times to look at the components of 
dialysis cost. Broadly speaking, these 
include equipment and supplies, phar-
maceuticals, consumables, clean water, 
trained technicians and nurses, and gov-
ernment taxes.4 Some of these costs can 
be higher in the developing than in the 
developed world. Th e ISN group hopes 
to tailor an eff ective but less costly form 
of peritoneal dialysis and hemodialysis 
in developing countries by carrying out 
pilot studies and working together with 
government and industry to make dialy-
sis more available. Interestingly, in a few 
centers in India, dialysis costs have been 
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reduced in some cases to as little as $10 
per session (without pharmaceuticals). 
It has become critical to dissect the cost 
components and to think through how 
they can be simplifi ed and reduced. Th e 
experience of Moosa and Kidd1 leads us 
to conclude that positive steps must be 
taken by the ISN, dialysis associations, 
and individuals to make RRT more 
available and at a lower cost in develop-
ing countries.
Current dialysis machines are more 
effective and self-regulated, but also 
more complicated, which makes them 
unsuitable in some developing coun-
tries. If industry can adapt to the needs 
of these countries, it is likely that the 
treatment can be applied to larger 
numbers. Simplifi cation of technology 
(which is not equivalent to inadequacy 
of dialysis of technology) can be a par-
tial answer where facilities for mainte-
nance and highly trained personnel are 
few. Innovation is needed at both gov-
ernment and technical levels to reduce 
costs of machines and solutions, and to 
simplify the regulatory climate.
Th e recent reduction in the transplan-
tation rate in the study area reported by 
Moosa and Kidd1 is disturbing. No clear 
explanation is given. Is it the result of a 
reduction in available surgical services 
or in nursing and technical personnel? 
Sustainability of health services is an 
absolute necessity, because lack of con-
sistency deters private and public invest-
ment and reduces confi dence. Although 
this has bedeviled many programs in 
Africa, it is surprising that this is a ques-
tion in one of the original transplanta-
tion groups there.
As the gap is widening globally 
between those who need kidney trans-
plants and the number available, it is 
clear that dialysis for transplantation 
alone may no longer be a suffi  cient crite-
rion for RRT. Th e World Health Organi-
zation envisages renal transplantation 
as the treatment of choice for end-stage 
renal disease but does not specifi cally 
address the problem of the develop-
ment of dialysis necessary for the vast 
majority of transplantation candidates. 
Th e superiority of transplantation over 
chronic dialysis in terms of outcomes 
and life quality is recognized. Th e fur-
ther advantages of live-donor surgery, 
preemptive or during chronic dialy-
sis, are obvious, but even these eff orts 
require dialysis backup.
Although it was not Moosa and 
Kidd’s1 purpose to discuss acute renal 
failure, it is important in the context of 
inadequate resources. Th e treatment of 
acute renal failure uses technology simi-
lar to that used for chronic kidney dis-
ease. Th is approach to acute renal failure 
is possible even in countries without the 
established chronic-dialysis and trans-
plantation methodology. It requires 
less centralization, emphasis on simple 
diagnostic measures, fewer trained indi-
viduals, and an objective of simplifying 
technology. However, the barriers are 
similar to those listed by Moosa and 
Kidd,1 particularly transportation, other 
health priorities, access to pure water, 
and personnel.
One could say that prevention of 
chronic kidney disease and vascular 
diseases such as hypertension and dia-
betes is the only viable health strategy 
in the developing world. Th is has been a 
major component of ISN programs and 
has been vigorously developed in tar-
geted units. However, prevention strate-
gies are not easy to establish in a region, 
let alone in a low-income nation. Th ey 
require a degree of sophistication within 
the health-care system and are not 
themselves without cost. Further, they 
require a careful monitoring of the tar-
geted patients to see whether the goals 
are being met. Although prevention 
must have priority for the longer term, 
treatment for those dying must be made 
available, if possible. It is noteworthy 
that the high cost of medical treatment 
is not limited to RRT but is relevant to 
other therapies as well — HIV antiret-
rovirals and cancer and cardiovascular 
therapies, to name a few.
Moosa and Kidd1 also remark on 
the lack of available skilled renal-care 
teams due to the ‘brain drain,’ exacer-
bated when opportunities to practice 
renal care are reduced. Th e exodus of 
physicians, nurses, and technicians to 
the United States, Canada, the United 
Kingdom, Australia, and other countries 
has led to a very substantial shortfall.5 
However serious the problem of the 
brain drain in South Africa, it is over-
shadowed by the problem in countries 
without any viable infrastructure to 
manage the problem of kidney diseases. 
South Africa has demonstrated its capa-
bility to train the best individuals with 
the condition that they remain home. 
Such programs need to be enhanced.
Although an individual physician’s 
desire to seek a more professionally 
rewarding life, as well as a better and 
more secure life for his or her family, 
deserves sympathy, the brain drain does 
seriously impair health care in develop-
ing countries. We believe it is also fair 
to ask why the United States, the United 
Kingdom, Canada, and others are con-
tributing to this diaspora. Surely devel-
oped countries should train an adequate 
number of their own health profession-
als for their own needs. Th is would be 
the fi rst step toward helping developing 
countries to retain their most talented 
health professionals.
International foundations and asso-
ciations should consider establishing 
training centers in developing countries 
and helping to develop secondary- and 
tertiary-care centers in selected devel-
oping countries so that qualifi ed physi-
cians and nurses can work at home. Th is 
is a critical step toward improving the 
health, economy, and self-reliance of a 
nation. Th e largest international agencies 
involved in health care (the World Health 
Organization, the Gates Foundation) do 
not generally fund the use of established 
technology but leave it to the relevant 
governments or other organizations. 
Finally, dialysis physicians who have left  
their country of origin could make a sig-
nifi cant volunteer contribution.6
Moosa and Kidd1 have served us well 
by being provocative about many of the 
fundamental issues of renal care. Should 
we be choosing who lives and who dies? 
While vigorously pursuing prevention 
of acute renal failure and chronic kid-
ney disease, should we not seek ways to 
make dialysis more aff ordable and acces-
sible? Should we be advocates for physi-
cians based in the developing world by 
training enough of our own? Th ese and 
other questions deserve more serious 
consideration from us as individuals, as 
nephrologists, and as medical societies.
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Is there a genotype–phenotype 
correlation in primary 
hyperoxaluria type 1?
BB Beck1 and B Hoppe1
There is ongoing debate about a genotype-phenotype correlation 
in patients with primary hyperoxaluria type 1 and specific AGXT 
mutations. However, other determinants like environmental factors 
or modifer genes may play a pivotal role in the heterogeneity of 
the disease. The report of Lorenzo and co-workers highlights this 
situation, presenting data of a whole population with just one specific 
AGXT mutation.
Kidney International (2006) 70, 984–986. doi:10.1038/sj.ki.5001797
Th e term ‘primary hyperoxaluria type 1’ 
(PH1) refers to a hepatic defect in glyoxy-
late metabolism, namely a decrease or even 
loss of alanine:glyoxylate aminotransferase 
(AGT) activity. Th e disease itself causes no 
liver dysfunction but manifests as the most 
severe known urolithiasis entity. Th is is 
true with respect to both stone burden and 
prognosis. PH1 is considered to be rare 
but surely remains underreported with an 
estimated prevalence ranging from one to 
three per million population in Europe 
and North America.1 Higher rates are 
reported from inbred populations. Un- or 
misdiagnosed PH1 patients can defi ni-
tively be found in many dialysis programs, 
as a substantial proportion (up to >30%) 
of patients is diagnosed late with end-stage 
renal failure (ESRF) or, even worse, more 
or less by chance aft er a biopsy specimen 
is obtained for suspected renal graft  rejec-
tion. There are several reasons for this 
dilemma. One is unfamiliarity with the 
rare monogenic disorder presenting with 
urolithiasis and with the linkage between 
stones and metabolic disorders. Th e fact 
that about half the children with stones, 
surprisingly, do not complain about pain 
or do so very little may unfortunately sup-
port this attitude. Second, while ESRF due 
to PH1 fortunately is rare in childhood, a 
number of patients are seen only in adult 
nephrology departments, which might 
make it more acceptable or simply neces-
sary to treat patients without established 
diagnosis. Th ird, with anuria present, the 
most valuable screening instrument, the 
determination of urinary oxalate excre-
tion, is no longer available.
PH1 is a mendelian disorder of auto-
somal-recessive inheritance with abso-
lute penetrance but extremely variable 
expressivity. Th e enzyme physiologically 
allocated to liver peroxisomes converts 
glyoxylate to glycine. In its absence or 
because of mistargeting to mitochondria, 
glyoxylate will be increasingly converted 
to oxalate and glycolate (Figure 1). Oxalate 
cannot be further metabolized in humans 
and therefore has to be cleared by the kid-
ney. Unfortunately, urine becomes quickly 
supersaturated with marked endogenous 
oxalate production. Nephrocalcinosis, 
which is crystal deposition within the dis-
tal tubular and collecting duct lumen, and 
recurrent stone formation are the clinical 
hallmarks of PH1 (Figure 1).1
Progressive nephrocalcinosis and recur-
rent urolithiasis along with their second-
ary complications (chronic interstitial 
infl ammation and fi brosis) result some-
how in chronic renal failure, which usu-
ally progresses to ESRF over time. Much 
worse than that, once signifi cant loss of 
renal function occurs, systemic deposi-
tion of calcium oxalate (systemic oxalosis) 
invariably takes place in various tissues, 
including the retina, myocardium, ves-
sel walls, central nervous system, bones, 
skin, and many more. Th is superimposes 
additional morbidity — for example, 
blindness; cardiomyopathy; arrhythmias, 
including heart block; oxalate osteopathy; 
treatment-resistant anemia; and so on.1 
No form of dialysis treatment will stop or 
reverse systemic oxalate deposition. Many 
of the complications take years to reverse 
aft er combined kidney–liver transplanta-
tion; sadly, some, such as loss of vision, 
are irreversible.
The remarkable single-center study 
by Lorenzo and co-workers2 (this issue) 
describes impressively the devastating 
course of systemic oxalosis not in a single 
patient but for a whole population — no 
small thing considering the relative paucity 
of long-term data. Th ey clearly outline sev-
eral key points regarding the clinical course 
of PH1:
(1)  PH1 patients who stay on chronic 
(hemo)dialysis are likely to die from 
systemic oxalosis.
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